clinical trial · NCT06035744
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Advanced Solid TumorCLN-617Pembrolizumab
brief summary
CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors
started
Dec 12, 2023
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Mar 3, 2025
official title
A Phase 1 First-in-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol